These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 25208474)

  • 21. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing.
    Schiffman M
    Cancer; 2007 Jun; 111(3):145-53. PubMed ID: 17487850
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil): profile report.
    Siddiqui MA; Perry CM
    BioDrugs; 2006; 20(5):313-6. PubMed ID: 17025377
    [No Abstract]   [Full Text] [Related]  

  • 23. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination.
    Naud PS; Roteli-Martins CM; De Carvalho NS; Teixeira JC; de Borba PC; Sanchez N; Zahaf T; Catteau G; Geeraerts B; Descamps D
    Hum Vaccin Immunother; 2014; 10(8):2147-62. PubMed ID: 25424918
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Implementation of HPV vaccination in Germany].
    Schreckenberger C; Kaufmann AM; Schneider A
    Dtsch Med Wochenschr; 2007 Oct; 132(42):2221-4. PubMed ID: 17926251
    [No Abstract]   [Full Text] [Related]  

  • 25. Screening for cervical cancer: controversy and contention or thoughtful analysis.
    Frable WJ
    Cancer; 2007 Jun; 111(3):143-4. PubMed ID: 17487849
    [No Abstract]   [Full Text] [Related]  

  • 26. Immunogenicity, reactogenicity, and safety of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women: interim analysis of a phase II, double-blind, randomized controlled trial at month 7.
    Konno R; Dobbelaere KO; Godeaux OO; Tamura S; Yoshikawa H
    Int J Gynecol Cancer; 2009 Jul; 19(5):905-11. PubMed ID: 19574783
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.
    David MP; Van Herck K; Hardt K; Tibaldi F; Dubin G; Descamps D; Van Damme P
    Gynecol Oncol; 2009 Dec; 115(3 Suppl):S1-6. PubMed ID: 19217149
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gynaecological cancer: HPV vaccine: is age just a number?
    Stone L
    Nat Rev Urol; 2014 Nov; 11(11):605. PubMed ID: 25245243
    [No Abstract]   [Full Text] [Related]  

  • 29. Prevention of cervical cancer through vaccination of adolescents.
    Pichichero ME
    Clin Pediatr (Phila); 2006 Jun; 45(5):393-8. PubMed ID: 16891270
    [No Abstract]   [Full Text] [Related]  

  • 30. Success of HPV vaccination is now a matter of coverage.
    Schiffman M; Wacholder S
    Lancet Oncol; 2012 Jan; 13(1):10-2. PubMed ID: 22075169
    [No Abstract]   [Full Text] [Related]  

  • 31. [Vaccination against human papillomavirus. Implementation and efficacy against cervical cancer control].
    Bégué P; Henrion R; Blanc B; Girard M; Sancho-Garnier H
    Bull Acad Natl Med; 2007 Dec; 191(9):1805-16; discussion 1816-7. PubMed ID: 18663976
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases.
    Skinner SR; Apter D; De Carvalho N; Harper DM; Konno R; Paavonen J; Romanowski B; Roteli-Martins C; Burlet N; Mihalyi A; Struyf F
    Expert Rev Vaccines; 2016; 15(3):367-87. PubMed ID: 26902666
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cervarix®: a bivalent vaccine against HPV types 16 and 18, with cross-protection against other high-risk HPV types.
    Szarewski A
    Expert Rev Vaccines; 2012 Jun; 11(6):645-57. PubMed ID: 22873123
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [HPV vaccination and cervical cancer screening].
    Sigurdsson K
    Laeknabladid; 2007 Dec; 93(12):819, 821. PubMed ID: 18057470
    [No Abstract]   [Full Text] [Related]  

  • 35. Regulation of immune responses to HPV infection and during HPV-directed immunotherapy.
    Bhat P; Mattarollo SR; Gosmann C; Frazer IH; Leggatt GR
    Immunol Rev; 2011 Jan; 239(1):85-98. PubMed ID: 21198666
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human papilloma virus vaccine and a few facts.
    Puwar T; Puwar B
    Indian J Med Sci; 2009 Jul; 63(7):309-10. PubMed ID: 19700913
    [No Abstract]   [Full Text] [Related]  

  • 37. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
    Jenkins D
    Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S18-25. PubMed ID: 18653221
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CDC panel backs routine HPV vaccination.
    Kuehn BM
    JAMA; 2006 Aug; 296(6):640-1. PubMed ID: 16896097
    [No Abstract]   [Full Text] [Related]  

  • 39. [Impact of vaccination against oncogenic human papillomavirus on the incidence and mortality of cervical cancer in Germany].
    Schneider A; Schwarz TF; Hammerschmidt T; Siebert U
    Med Klin (Munich); 2007 Jul; 102(7):515-23. PubMed ID: 17634869
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Papillomavirus vaccine types 16 and 18: new drug. Cervical cancer: just another vaccine.
    Prescrire Int; 2008 Jun; 17(95):103-4. PubMed ID: 18623911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.